Rapid Multiplex Elisa Assay

Description: ELISA

Description: ELISA

Description: ELISA

Description: ELISA

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure IgG antibodies against the mutants is in urgent need.

Description: Cell Culture Supernatant and Other Biological Samples

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.Omicron BA.2.75 (a sub-variant of the BA.2 lineage) appears more transmissible than BA.5 in India and Nepal. Moreover, the World Health Organization (WHO) has lately classified BA.2.75 as a variant of concern lineages under monitoring (VOC-LUM).

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure IgG antibodies against the mutants is in urgent need.

Description:

Product Overview

_x000D_

The Multiplex ELISA Kit For Human Malaria (5-Plex) is a robust and fully quantitative chemiluminescent assay for the concurrent surveillance of four malaria biomarkers. The assay simultaneously measures HRP2, LDH-Pan, LDH-Pv, LDH-Pf, and one host biomarker, CRP. The monitoring of subclinical Malaria infections and prevalence of HRP2-deletions is achieved by the coupling of the most sensitive commercially available HPR2 assay with LDH detection. Validated protocols for whole blood samples are in place, with protocols for dry blood spots in development.

Each kit contains a 96-well plate and all other reagents necessary to perform the assay. The individual wells of the plate are precisely and reproducibly arrayed with each of the five biomarkers for accurate results.

In 3.5 hours, each kit will report quantities of 80 samples for the four Malaria biomarkers and one host biomarker CRP. This is achieved while only using 15 μl of whole blood per sample.

_x000D__x000D_

Assay Ranges

_x000D_

Analyte	Assay Type	Calibrator Range	Upper Limit of Quantification (ULOQ)	Lower Limit of Quantification (LLOQ)	Limit of Detection
CRP	Competitive	62,800 – 61 (ng/mL)	11,125 (ng/mL)	60 (ng/mL)	30.5 (ng/mL)
HRP2	Sandwich	950 – 0.9 (pg/mL)	675 (pg/mL)	0.92 (pg/mL)	0.45 (pg/mL)
LDH -Pan	Sandwich	70,750 – 69 (pg/mL)	17,687.5 (pg/mL)	24 (pg/mL)	34.5 (pg/mL)
LDH-Pf	Sandwich	22,500 - 22 (pg/mL)	5,750 (pg/mL)	8 (pg/mL)	11 (pg/mL)
LDH-Pv	Sandwich	43,750 – 43 (pg/mL)	5,000 (pg/mL)	6 (pg/mL)	21.5 (pg/mL)

_x000D__x000D_

Kit Components

_x000D_

Each kit contains a 96-well plate (solid plate), with relevant biomarker panel in each well, and contains all reagents required to perform testing. If you want a strip-well format, please contact us for customization.

_x000D__x000D_

Reagents include:

_x000D_

Wash Buffer Concentrate (20X): Liquid, 50 mL/vial of a concentrated solution of buffered surfactant;_x000D_Assay Diluent: Liquid, 6 mL/vial of a buffered protein solution with heterophilic antibody and rheumatoid factor blockers and preservatives;_x000D_Calibrator Diluent: Lyophilized, buffered protein solution containing preservatives;_x000D_Competitor: Lyophilized, biotinylated competitive antigen;_x000D_Detection Mix: Liquid, 6 mL/vial of biotinylated antibodies in a buffered protein solution with preservatives;_x000D_Calibrator: Lyophilized, recombinant antigens in a buffered protein base;_x000D_Streptavidin-HRP (1X): Liquid, 6 mL/vial of streptavidin-conjugated horseradish peroxidase;_x000D_Substrate A+: Liquid, 3 mL/vial of stabilized hydrogen peroxide;_x000D_Substrate B: Liquid, 3 mL/vial of stabilized signal enhancer;_x000D_Plate Seals (3): Adhesive strips

Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.